Evidence map›Paper›PMID 31615443›Full record

ArticleBMC infectious diseases2019

Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.

Pedro Surriabre, Andrea Torrico, Tania Vargas, Fuantina Ugarte, Patricia Rodriguez, Véronique Fontaine

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Pedro SurriabreLaboratorio de Virología, Facultad de Medicina, Universidad Mayor de San Simón, Cochabamba, Bolivia.
Andrea TorricoLaboratorio de Virología, Facultad de Medicina, Universidad Mayor de San Simón, Cochabamba, Bolivia.
Tania VargasLaboratorio de Virología, Facultad de Medicina, Universidad Mayor de San Simón, Cochabamba, Bolivia.
Fuantina UgarteCIES Salud Sexual y Reproductiva, Regional Cochabamba, Bolivia.
Patricia RodriguezLaboratorio de Virología, Facultad de Medicina, Universidad Mayor de San Simón, Cochabamba, Bolivia.
Véronique FontaineUnité de Microbiologie Pharmaceutique et Hygiène, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), Brussels, Belgium. Veronique.Fontaine@ulb.ac.be.ORCID http://orcid.org/0000-0001-7588-5462
Universidad Mayor de San Simón · BOUniversité Libre de Bruxelles · BE

Funding

Académie de recherche et d'enseignement supérieur PRD2013
6 · The paper itself

Abstract

backgroundHPV test implementation as a primary screening tool has the potential to decrease cervical cancer incidence as shown by several studies around the world. However, in many low-resource settings, the HPV test introduction has been backed down mainly due to its price. In this study, we present a novel low-cost strategy involving simple devices and techniques for high-risk human papillomavirus (HR-HPV) detection. The analytical performance to detect HR-HPV infections of this novel strategy was assessed by comparing it with the Hybrid Capture 2 system (HC2), which is used as gold standard.

methodsPaired-cervical samples were collected from 541 women assisting to gynecological services in an outpatient clinic. One sample was transported in the Hybrid Capture Standard Transport Medium for HR-HPV detection by the HC2. The second sample was transported on glass slide for detection by PCR-based techniques (GP-EIA, BSGP-EIA and pU 1 M-L/2R).

resultsThe level of agreement between the PCR-based techniques and HC2 system was determined with the Cohen's kappa value. The kappa values between HC2 and GP-EIA, BSGP-EIA and pU 1 M-L/2R were 0.71 (CI 95% 0.63-0.78), 0.78 (CI 95% 0.71-0.84) and 0.63 (CI 95% 0.55-0.72), respectively. However, when the results from both BSGP-EIA and pU 1 M-L/2R were combined, the level of agreement with HC2 was increased to 0.82 (CI 95% 0.76-0.88), reflecting a very good agreement between the two HR-HPV detection strategies. Furthermore, the sensitivity of both techniques combined was also increased compared to the BSGP-EIA (88.7% vs 77.4%) and the pU (88.7 vs 60.9%) without penalizing the specificity obtained with the BSGP-EIA (95.1% vs 96.9%) and the pU (95.1% vs 96.5%).

conclusionsThis novel strategy, combining two PCR-based techniques for HR-HPV detection, could be useful for cervical cancer screening in self-collected samples in low-income countries.

Indexed as

Cervix UteriDNA, ViralEarly Detection of CancerFemaleGenotypeHumansPapillomaviridaePapillomavirus InfectionsPolymerase Chain ReactionReagent Kits, DiagnosticRiskSensitivity and SpecificitySequence Analysis, DNAUterine Cervical NeoplasmsDNA, ViralReagent Kits, DiagnosticCollection devicesEIAHPV screeningHuman papillomavirusPCR BSGPpU

Identifiers

PMID31615443
PMCPMC6794773
OpenAlexW2980731027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.